The combined use of low‐dose aspirin with a low‐dose FXa inhibitor6 or with an effective P2Y12 inhibitor represents a rational approach to reduce residual CV risk of patients with ASCVD, in light of the multifactorial nature of atherothrombosis.16 The gene discussed is P2RY12; the disease is atherosclerosis.